Joy Peter

940 total citations
24 papers, 695 citations indexed

About

Joy Peter is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, Joy Peter has authored 24 papers receiving a total of 695 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hepatology, 16 papers in Epidemiology and 8 papers in Rheumatology. Recurrent topics in Joy Peter's work include Hepatitis C virus research (19 papers), Liver Disease Diagnosis and Treatment (14 papers) and Hepatitis B Virus Studies (6 papers). Joy Peter is often cited by papers focused on Hepatitis C virus research (19 papers), Liver Disease Diagnosis and Treatment (14 papers) and Hepatitis B Virus Studies (6 papers). Joy Peter collaborates with scholars based in United States and Germany. Joy Peter's co-authors include David R. Nelson, Keith D. Lindor, Jill C. Keach, Virginia Clark, Michael Fried, Paul Angulo, Manal F. Abdelmalek, Schuyler O. Sanderson, Consuelo Soldevila‐Pico and Craig J. McClain and has published in prestigious journals such as Gastroenterology, Hepatology and Scientific Reports.

In The Last Decade

Joy Peter

23 papers receiving 682 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joy Peter United States	12	536	504	91	87	63	24	695
Jesús Castillo Spain	13	522 1.0×	500 1.0×	130 1.4×	103 1.2×	34 0.5×	26	872
Jeng‐Fu Yang Taiwan	17	813 1.5×	685 1.4×	160 1.8×	76 0.9×	37 0.6×	41	998
Keisuke Ojiro Japan	14	373 0.7×	293 0.6×	59 0.6×	145 1.7×	48 0.8×	30	653
Ching‐I Huang Taiwan	15	747 1.4×	659 1.3×	111 1.2×	73 0.8×	39 0.6×	87	956
Sonia Rossi Italy	11	742 1.4×	684 1.4×	58 0.6×	51 0.6×	27 0.4×	14	928
Mahmoud Khattab Egypt	14	650 1.2×	623 1.2×	81 0.9×	44 0.5×	41 0.7×	35	812
Beat Helbling Switzerland	13	767 1.4×	659 1.3×	193 2.1×	73 0.8×	52 0.8×	20	945
Shinn‐Chern Chen Taiwan	17	672 1.3×	612 1.2×	148 1.6×	64 0.7×	24 0.4×	38	831
Angeline Oi–Shan Lo Hong Kong	13	943 1.8×	730 1.4×	137 1.5×	157 1.8×	34 0.5×	22	1.2k
Xiaojuan Ou China	17	642 1.2×	558 1.1×	73 0.8×	183 2.1×	23 0.4×	93	939

Countries citing papers authored by Joy Peter

Since Specialization

Citations

This map shows the geographic impact of Joy Peter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joy Peter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joy Peter more than expected).

Fields of papers citing papers by Joy Peter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joy Peter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joy Peter. The network helps show where Joy Peter may publish in the future.

Co-authorship network of co-authors of Joy Peter

This figure shows the co-authorship network connecting the top 25 collaborators of Joy Peter. A scholar is included among the top collaborators of Joy Peter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joy Peter. Joy Peter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Park, Haesuk, Wei‐Hsuan Lo‐Ciganic, James L. Huang, et al.. (2022). Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection. Scientific Reports. 12(1). 18094–18094. 5 indexed citations

Lok, Anna S., Juhi Moon, Kenneth E. Sherman, et al.. (2022). Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study. Clinical Gastroenterology and Hepatology. 21(2). 546–548.e4. 1 indexed citations

Park, Haesuk, Wei‐Hsuan Lo‐Ciganic, James L. Huang, et al.. (2022). Machine learning algorithms for predicting direct‐acting antiviral treatment failure in chronic hepatitis C: An HCV‐TARGET analysis. Hepatology. 76(2). 483–491. 21 indexed citations

Evon, Donna M., Meichen Dong, Bryce B. Reeve, et al.. (2022). Sustainable and equivalent improvements in symptoms and functional well‐being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial. Journal of Viral Hepatitis. 29(9). 795–806. 1 indexed citations

Wang, Gary P., Gretja Schnell, Jens Kort, et al.. (2021). Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir. Journal of Hepatology. 75(4). 820–828. 1 indexed citations

Lok, Anna S., Mark Sulkowski, Jens Kort, et al.. (2019). Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. Gastroenterology. 157(6). 1506–1517.e1. 34 indexed citations

Wang, Gary P., Norah A. Terrault, Jacqueline D. Reeves, et al.. (2018). Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. Scientific Reports. 8(1). 3199–3199. 18 indexed citations

Lok, A.S., Ira Willner, Federico Hinestrosa, et al.. (2018). A phase 3b, open-label, randomized, pragmatic study of glecaprevir/pibrentasvir +/− ribavirin (RBV) for HCV genotype 1 subjects who previously failed an NS5A Inhibitor + sofosbuvir (SOF) therapy. Journal of Hepatology. 68. S104–S104. 1 indexed citations

Reeves, Jacqueline D., Norah A. Terrault, Joseph K. Lim, et al.. (2016). Prevalence and Impact of Baseline Resistance-Associated Variants on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir against GT1 HCV Infection: Hcv-Target Interim Analysis. Journal of Hepatology. 64(2). S187–S188. 3 indexed citations

10.

Morelli, Giuseppe, Roberto J. Firpi, Joy Peter, et al.. (2015). Open-Label Study to Evaluate the Safety & Tolerability of Telaprevir in Combination with Sofosbuvir in Naive Subjects with HCV Genotype 1 Short Title: Telaprevir & Sofosbuvir in HCV Genotype 1. Journal of Gastroenterology and Hepatology Research. 4(5). 1599–1604. 2 indexed citations

11.

Reddy, K. Rajender, Joseph K. Lim, Alexander Kuo, et al.. (2015). O007 : All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: Interim report from the HCV-target real world experience. Journal of Hepatology. 62. S193–S193. 27 indexed citations

12.

Gordon, Stuart C., Andrew J. Muir, Joseph K. Lim, et al.. (2014). Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET. Journal of Hepatology. 62(2). 286–293. 72 indexed citations

13.

Clark, Virginia, Joy Peter, & David R. Nelson. (2013). New therapeutic strategies in HCV: second‐generation protease inhibitors. Liver International. 33(s1). 80–84. 40 indexed citations

14.

Levy, Cynthia, Joy Peter, David R. Nelson, et al.. (2010). Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Alimentary Pharmacology & Therapeutics. 33(2). 235–242. 133 indexed citations

15.

Abdelmalek, Manal F., Schuyler O. Sanderson, Paul Angulo, et al.. (2009). Betaine for nonalcoholic fatty liver disease. Hepatology. 50(6). 1818–1826. 176 indexed citations

16.

Fried, Michael, Joy Peter, Keith Hoots, et al.. (2002). Hepatitis C in adults and adolescents with hemophilia: A randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology. 36(4). 967–972. 56 indexed citations

17.

Duncan, Alexander, et al.. (2001). Serum hyaluronic acid in patients with veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplantation. 27(6). 635–639. 19 indexed citations

18.

Fried, Michael, Mitchell L. Shiffman, Richard K. Sterling, et al.. (2000). A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype. The American Journal of Gastroenterology. 95(11). 3225–3229. 47 indexed citations

19.

Fried, MW, et al.. (1998). A multicenter, randomized trial of daily, high dose interferon-alpha 2b for the treatment of chronic hepatitis C: Prospective stratification by viral burden and genotype. Gastroenterology. 114. A1242–A1242. 10 indexed citations

20.

Booyens, J, et al.. (1954). A comparison of oral and rectal temperatures.. PubMed. 19(4). 169–169.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact